

# Treatment patterns and outcomes according to cytogenetics in patients with multiple myeloma: a real-world analysis

Blood Cancer Journal

12, 46

DOI: [10.1038/s41408-022-00638-0](https://doi.org/10.1038/s41408-022-00638-0)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Exploring the current molecular landscape and management of multiple myeloma patients with the t(11;14) translocation. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	7
2	The prognostic value of the MASS in a multi-center cohort of patients with newly diagnosed multiple myeloma. <i>Blood Cancer Journal</i> , 2022, 12, .	2.8	0
3	Single-cell transcriptome profiling reveals the key role of ZNF683 in natural killer cell exhaustion in multiple myeloma. <i>Clinical and Translational Medicine</i> , 2022, 12, .	1.7	11
4	The adverse impact of a gain in chromosome 1q on the prognosis of multiple myeloma treated with bortezomib-based regimens: A retrospective single-center study in China. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
5	Treatment attrition rates and relevant risk factors in multiple myeloma: A real-world study in China. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	1
6	Clinical Relevance of Interferon Regulatory Family-4 (IRF4) Expression in Newly Diagnosed Patients with Multiple Myeloma. <i>Indian Journal of Hematology and Blood Transfusion</i> , 0, , .	0.3	0
7	Efficacy and safety of venetoclax-based regimens for the treatment of relapsed/refractory multiple myeloma: a systemic review and meta-analysis. <i>Therapeutic Advances in Hematology</i> , 2023, 14, 204062072311550.	1.1	0
8	Attrition Rates in Multiple Myeloma Treatment under Real World Conditions—An Analysis from the Austrian Myeloma Registry (AMR). <i>Cancers</i> , 2023, 15, 962.	1.7	3
9	The R2-ISS in a Multicenter Cohort of Chinese Patients With Newly Diagnosed Multiple Myeloma. <i>HemaSphere</i> , 2023, 7, e857.	1.2	3